Table III.

	N	Overall Survival				Progression-free Survival
		2-yr (95% CI)	4-yr (95% CI)	HR (95% CI)	P-value	2-yr (95% CI)	4-yr (95% CI)	HR (95% CI)	P-value
Overall	44	0.54 (0.41–0.72)	0.42 (0.28–0.63)	-	-	0.31 (0.19–0.5)	0.18 (0.09–0.4)	-	-
Gender					0.91				0.46
Female	13	0.57 (0.34–0.95)	0.43 (0.2–0.92)	(reference)		0.51 (0.29–0.9)	-	(reference)
Male	31	0.53 (0.38–0.75)	0.42 (0.26–0.68)	1.05 (0.43–2.57)		0.24 (0.12–0.47)	0.19 (0.08–0.43)	1.35 (0.6–3.03)
Age					0.007				0.02
Less than 55	20	0.79 (0.62–1)	0.7 (0.5–0.98)	(reference)		0.46 (0.26–0.79)	0.27 (0.11–0.68)	(reference)
55 or older	24	0.35 (0.19–0.62)	0.21 (0.08–0.52)	3.72 (1.43–9.65)		0.2 (0.09–0.45)	0.13 (0.04–0.42)	2.46 (1.17–5.14)
Prior Lines of Therapy					0.34				0.44
3–4 lines	12	0.67 (0.45–0.99)	0.57 (0.35–0.94)	(reference)		0.42 (0.21–0.81)	0.25 (0.09–0.67)	(reference)
5–6 lines	16	0.60 (0.39–0.91)	0.48 (0.26–0.88)	1.17 (0.38–3.57)		0.41 (0.22–0.76)	0.27 (0.1–0.75)	0.99 (0.40–2.41)
> 6 lines	16	0.33 (0.14–0.76)	-	2.04 (0.70–5.95)		0	0	1.64 (0.65–4.12)
Donor					0.68				0.55
Related	14	0.56 (0.35–0.9)	0.38 (0.18–0.78)	(reference)		0.30 (0.12–0.73)	0.1 (0.02–0.62)	(reference)
Unrelated	30	0.53 (0.37–0.76)	0.47 (0.3–0.73)	0.84 (0.36–1.95)		0.32 (0.18–0.56)	0.25 (0.12–0.52)	0.80 (0.39–1.65)
Match					0.65				0.33
10/10 Unrelated	18	0.57 (0.36–0.9)	0.57 (0.36–0.9)	(reference)		0.36 (0.18–0.72)	0.36 (0.18–0.72)	(reference)
9/10 Unrelated	12	0.44 (0.22–0.89)	0.29 (0.1–0.85)	1.29 (0.43–3.89)		0.25 (0.08–0.73)	0.12 (0.02–0.72)	1.60 (0.63–4.08)
Extramedullary Manifestation					0.01				0.003
Absent	31	0.66 (0.51–0.86)	0.53 (0.36–0.79)	(reference)		0.41 (0.26–0.67)	0.30 (0.15–0.58)	(reference)
Present	13	0.31 (0.14–0.7)	0.21 (0.07–0.64)	2.90 (1.27–6.60)		0.08 (0.01–0.51)	0	2.99 (1.45–6.18)
Pre-Transplant Status					0.03				0.12
VGPR/CR	23	0.62 (0.44–0.87)	0.62 (0.44–0.87)	(reference)		0.4 (0.24–0.68)	0.22 (0.09–0.53)	(reference)
PR	21	0.47 (0.29–0.74)	0.19 (0.06–0.6)	2.56 (1.1–5.97)		0.14 (0.03–0.7)	0.14 (0.03–0.7)	1.66 (0.82–3.39)